The groundbreaking rise of Viagra presented a massive chance for shareholders , but its patent has expired , creating a challenging landscape. Generic versions have entered the space , eroding profits and putting pressure on profit percentages . While established pharmaceutical companies maintain a stake in this area, the potential remains clouded